Eli Lilly and Company (NYSE:LLY) received a $73.00 price target from BMO Capital Markets in a research report issued to clients and investors on Wednesday, November 1st. The brokerage currently has a “sell” rating on the stock. BMO Capital Markets’ price objective points to a potential downside of 11.50% from the company’s current price.
Several other brokerages also recently commented on LLY. Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the stock a “hold” rating in a research note on Friday, October 6th. Leerink Swann upped their price objective on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Credit Suisse Group AG downgraded Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their price objective for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research note on Friday, October 13th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $89.76.
Eli Lilly and (NYSE LLY) traded down $0.37 during mid-day trading on Wednesday, reaching $82.49. The company had a trading volume of 2,684,797 shares, compared to its average volume of 3,724,201. The firm has a market capitalization of $91,240.00, a P/E ratio of 20.36, a PEG ratio of 1.83 and a beta of 0.34. Eli Lilly and has a fifty-two week low of $64.18 and a fifty-two week high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.88 earnings per share. analysts anticipate that Eli Lilly and will post 4.22 EPS for the current fiscal year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold a total of 772,003 shares of company stock valued at $64,837,441 in the last quarter. 0.20% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Ronna Sue Cohen boosted its position in shares of Eli Lilly and by 0.4% during the 2nd quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after acquiring an additional 9 shares during the last quarter. Accredited Investors Inc. boosted its position in shares of Eli Lilly and by 0.4% during the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after acquiring an additional 14 shares during the last quarter. Sunbelt Securities Inc. boosted its position in shares of Eli Lilly and by 0.5% during the 1st quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after acquiring an additional 17 shares during the last quarter. Northwest Quadrant Wealth Management LLC boosted its position in shares of Eli Lilly and by 0.5% during the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after acquiring an additional 19 shares during the last quarter. Finally, Oakworth Capital Inc. boosted its position in shares of Eli Lilly and by 0.3% during the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after acquiring an additional 20 shares during the last quarter. Hedge funds and other institutional investors own 75.48% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with our FREE daily email newsletter.